SCHEMBL3532745

SCHEMBL3532745

CCOC(=O)c1oc(C2(Br)CCCCC2)nc1CBr

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PLK1 P53350 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 10/20 0.35
KDM4E B2RXH2 10/20 0.35
HPGD P15428 6/20 0.35
MAPT P10636 4/20 0.35
HSD17B10 Q99714 4/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PARG Q86W56 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 2/20 0.34
GAA P10253 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12323577 0.75 PLK1 (0.44) NPC1PLK1L3MBTL1ALDH1A1KDM4E
SCHEMBL21177306 0.73 PLK1 (0.43) NPC1PLK1ALDH1A1KDM4EHPGD
SCHEMBL2778352 0.72 PLK1 (0.39) NPC1SMN1; SMN2PLK1ALDH1A1KDM4E
SCHEMBL3528640 0.71 ALDH1A1 (0.41) NPC1SMN1; SMN2L3MBTL1ALDH1A1KDM4E
SCHEMBL3536411 0.67 TARBP2 (0.62) NPC1SMN1; SMN2L3MBTL1ALDH1A1KDM4E
SCHEMBL3764200 0.65 KDM4E (0.51) KDM4EMAPT
SCHEMBL23214485 0.64 TARBP2 (0.40) NPC1PLK1L3MBTL1ALDH1A1KDM4E
SCHEMBL6177971 0.63 CYP1A2 (0.41) NPC1PLK1L3MBTL1ALDH1A1KDM4E
SCHEMBL25367845 0.62 LCAT (0.40) NPC1SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL13545979 0.62 PLK1 (0.43) NPC1PLK1L3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
CN-101272784-A Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals SANOFI AVENTIS (FR) 2008-09-24 CN disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG NPC1 1228/4885SMN1; SMN2 4379/4885PLK1 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.